XML 23 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Cash flows from operating activities:    
Net loss $ (47,252) $ (33,978)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock based compensation 10,362 9,746
Operating lease right-of-use asset 1,050 93
Depreciation 117 103
Amortization of premium on marketable debt securities 1,737
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets (418) 1,405
Other assets 295 58
Accounts payable 40 198
Accrued expenses 576 (966)
Operating lease liabilities (1,009) (66)
Net cash used in operating activities (34,502) (23,407)
Cash flows from investing activities:    
Cash and restricted cash acquired in connection with the reverse merger with ArTara Therapeutics, Inc. 3,719
Purchase of marketable debt securities (124,748)
Proceeds from maturity and redemption of marketable debt securities 27,150
Purchase of property and equipment (596) (884)
Net cash (used in)/provided by investing activities (98,194) 2,835
Cash flows from financing activities:    
Proceeds from - ArTara Private Placement, net of offering costs 1,867
Proceeds from - Common Stock in Proteon Private Placement, net of offering costs 12,413
Proceeds from - Series 1 Convertible Preferred Stock in Proteon Private Placement, net of offering costs 25,319
Proceeds from Common Offering, net of offering costs 73,570
Proceeds from Preferred Offering, net of offering costs 66,284
Proceeds from Underwriters Overallotment Option 11,087
Repayments under short-term debt (1,669)
Proceeds from the exercise of stock options 530
Repurchase of shares in connection with settlement of RSUs (228)
Net cash (used in)/provided by financing activities (228) 189,401
Net (decrease)/increase in cash and cash equivalents and restricted cash (132,924) 168,829
Cash and cash equivalents and restricted cash - beginning of year 169,393 564
Cash and cash equivalents and restricted cash - end of period 36,469 169,393
Cash paid for:    
Interest 34
Income Taxes
Supplemental schedule of non-cash activities:    
Deferred offering costs recognized that were previously recorded in accrued expenses 122
Purchase of insurance agreement with notes payable 1,669
Common stock issued in connection with the reverse merger with ArTara Therapeutics, Inc. $ 34,533